# Magenta Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/magenta-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.magentatx.com
- Total disclosed funding: $151M
- Latest round: Series C (Apr 9, 2018)
- Investors on record: 10

## About

Magenta Therapeutics, Inc. is a US-based biotechnology company focused on developing innovative therapies that harness the power of stem cells to address serious diseases. Their approach emphasizes cellular therapeutics aimed at transforming patient outcomes.Founded in 2015, Magenta Therapeutics, Inc. is dedicated to pioneering stem cell-based therapies. Headquartered in Cambridge, US, the company has successfully raised funding totaling USD 86.40 mn across multiple rounds, with its latest round, PIPE, occurring in June 2020, featuring investors like Deep Track Capital and OrbiMed Advisors. Jason Gardner serves as the CEO, and the company has made significant strides, including raising USD 100 million in an IPO in June 2018.Magenta Therapeutics specializes in developing advanced biotechnological solutions, primarily focusing on stem cell therapies aimed at treating various serious diseases. The company's core products are designed to promote efficient patient care through innovative treatments that enhance the healing process. Their offerings have gained traction among healthcare providers and researchers seeking effective solutions in transplant medicine. Magenta Therapeutics markets its therapies globally, with a strong emphasis on collaboration with medical institutions to improve patient outcomes.For the most recent fiscal year 2023, Magenta Therapeutics reported revenue of USD 2.83 mn and an EBITDA of USD -44.97 mn. The company employs a subscription-based model for its services, which enables healthcare partners to access their innovative therapies while fostering direct relationships with end-users.Magenta Therapeutics plans to expand its product lineup with new stem cell therapies that are currently in development, aiming for launches in the upcoming years. The company is also targeting expansion into European and Asian markets by 2025 to increase its global footprint. The recent funding of USD 86.40 mn will support these initiatives, particularly in advancing clinical trials and product development, enhancing the company's capability to deliver innovative solutions in regenerative medicine.

## Funding rounds

- Series C, Apr 9, 2018, $52M — Access Industries, Casdin Capital, EcoR1 Capital, Eventide Asset Management, Be The Match BioTherapies, Watermill Asset Management
- Series B, May 2, 2017, $50M — Atlas Venture, Access Industries, Third Rock Ventures, GV, Mass General Brigham Ventures, Casdin Capital, Be The Match BioTherapies
- Series A, Nov 16, 2016, $49M — Atlas Venture, Access Industries, Third Rock Ventures, GV, Mass General Brigham Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series A, Series B, Series C
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B, Series C
- Be The Match BioTherapies — Series B, Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series C
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series C
- Watermill Asset Management — Series C